Loading...
NPI 1326386939 · Garden City Park, NY · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Truetox Laboratories LLC is a clinical medical laboratory provider located in Garden City Park, New York. This profile covers 3 Medicare and 44 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Truetox Laboratories LLC |
| Address | 50 Rose Place |
| City | Garden City Park |
| State | NY |
| ZIP | 11040 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | January 17, 2013 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $56.4M |
| Medicare | $647.5K |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3,130 | $110 | $350.1K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 4,720 | $60 | $287.6K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 80 | $150 | $12.2K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 3 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
44 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 648,160 | $40 | $24M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 257,490 | $80 | $20.3M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 76,640 | $110 | $8.6M |
| 80348 | The lab analyst measures the amount of or detects the presence of buprenorphine in a patient specimen. Buprenorphine is a drug used to treat opioid addiction, to control acute pain in individuals who… | 87,240 | $10 | $610.7K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2,620 | $150 | $390.4K |
| 80346 | The lab analyst measures the amount of or detects the presence of one to twelve benzodiazepines, which are tranquilizers, in a patient specimen. | 94,650 | $1 | $378.6K |
| 80336 | The lab analyst measures the amount of or detects the presence of three to five tricyclic and other cyclicals antidepressants, which are psychiatric medications, in a patient specimen. | 23,480 | $10 | $281.7K |
| 80354 | The lab analyst measures the amount of or detects the presence of fentanyl in the patient specimen. | 52,220 | $1 | $208.9K |
| 80349 | The lab analyst measures the amount of or detects the presence of natural cannabinoids in a patient specimen. | 42,450 | $1 | $169.8K |
| 80356 | The lab analyst measures the amount of or detects the presence of heroin metabolite in the patient specimen. | 44,510 | $1 | $133.5K |
Showing 1–10 of 44
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
44 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 40 | 440 | $90 | $511.9K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 110 | 690 | $50 | $442K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1 | 290 | 1,900 | $30 | $390.6K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 26 | 30 | 550 | $100 | $359.8K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5 | 20 | 240 | $70 | $302K |
| 80344 | The lab analyst measures the amount of or detects the presence of seven or more antipsychotics, in a patient specimen. The antipsychotics that the analyst measures are not specified by other CPT®… | 2 | 10 | 2,250 | $10 | $99.1K |
| 80352 | The lab analyst measures the amount of or detects the presence of seven or more synthetic cannabinoids present in the patient specimen. | 2 | 10 | 950 | $10 | $83.8K |
| 80338 | The lab analyst measures the amount of or detects the presence of antidepressants, which are psychiatric medications, in a patient specimen. The antidepressants the provider is testing for are not… | 3 | 10 | 1,970 | $1 | $67.9K |
| 80370 | The lab analyst measures the amount of or detects the presence of three or more skeletal muscle relaxants in the patient specimen. These drugs reduce the tone of skeletal muscles and thus alleviate… | 8 | 10 | 610 | $10 | $65.8K |
| 83992 | The lab analyst measures the level of this drug, phencyclidine, typically in a urine or blood sample. This very potent street drug is a common drug of abuse. | 13 | 20 | 580 | $10 | $61.4K |
Showing 1–10 of 44
Other providers in the same ZIP code as Truetox Laboratories LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Long Island Jewish Medical Center | NY | General Acute Care Hospital | $0 | $370.9M |
| Advanced Dermatology PC | NY | Dermatology Physician | $0 | $43.9M |
| United Seating And Mobility LLC | NY | Durable Medical Equipment & Medical Supplies | $0 | $21M |
| Allen Rothpearl | NY | Diagnostic Radiology Physician | $433.2K | $12.2M |
| United Sleep Diagnostics Inc | NY | Sleep Disorder Diagnostic Clinic/Center | $828.3K | $4.4M |
| Edward Rutkovsky | NY | Internal Medicine Physician | $2.1M | $10.3K |
| Nimish Dharia | NY | Cardiovascular Disease Physician | $1.4M | $37.4K |
| Vincent Macaluso | NY | Neurology Physician | $1.3M | $0 |
| Sajid Khan | NY | Internal Medicine Physician | $623K | $373.8K |
| Sarat Bhumi | NY | Cardiovascular Disease Physician | $569K | $367.9K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.